Mineralys in Radnor Sees Stock Price Explode

Mineralys in Radnor Sees Stock Price Explode After Hypertension Drug Test
The Radnor biopharmaceutical firm Mineralys Therapeutics saw its stock price hit new heights Monday after a positive late-stage clinical trial showed promise
Mineralys Reports Positive Results for Hypertension Drug Lorundrostat
Mineralys Therapeutics, Inc. (Nasdaq: MLYS) has announced positive topline results from its pivotal Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating lorundrostat for the treatment of uncontrolled
Mineralys Therapeutics' stock price explodes after lorundrostat study results
A Radnor biopharma firm saw its stock price skyrocket after the company posted positive late-stage clinical trial results for its lead new drug candidate.
Mineralys Therapeutics Announces Pricing of $175.0 Million Underwritten Public Offering of Common Stock
BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.
Mineralys' stock jumps as hypertension drug posts double clinical wins
Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of hypertension.
Mineralys Therapeutics Unveils Positive Data From Two Trials For Hypertension Drug Candidate
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) released topline data from its pivotal Launch-HTN Phase 3 and pivotal Advance-HTN Phase 2 trials of lorundrostat for uncontrolled hypertension (uHTN) or resistant hypertension (rHTN).
Mineralys Therapeutics 12.96M share Secondary priced at $13.50
The deal size was reduced to $175M from $250M and priced below last closing price of $14.30. BofA, Evercore ISI, Goldman Sachs, Stifel and
Positive Topline Results for Lorundrostat in Hypertension
Two pivotal trials of the aldosterone synthase inhibitor have shown positive results for lorundrostat in uncontrolled and resistant hypertension.
Mineralys' drug for persistent hypertension succeeds in two trials
Mineralys Therapeutics said on Monday its lead drug significantly lowered blood pressure in patients with difficult-to-treat hypertension in late- and mid-stage trials.
Mineralys Therapeutics prices $175M stock offering
Mineralys Therapeutics (MYLS) priced an underwritten public offering of ~12.96M shares at a public offering price of $13.50 per share. The aggregate gross proceeds are expected to be ~$175M. Underwriters have a 30-day option to purchase up to an additional ~1.
BioPharma Dive4d
Mineralys shares climb on study data for blood pressure drug
Findings from a pair of studies in tough-to-treat hypertension establish Mineralys’ drug as a “derisked, almost-commercial ...
GlobalData on MSN4d
Mineralys’s stock soars as hypertension pill scores in two pivotal trials
Mineralys Therapeutics’s oral hypertension therapy, lorundrostat, has met the primary endpoint in two pivotal studies, ...
Mineralys: Prospects Just Got Better With Successful Pivotal Data Readouts
Primary endpoints of both Advance-HTN and Launch-HTN studies, using lorundrostat to treat patients with hypertension were met ...
Bank of America Securities Sticks to Its Buy Rating for Mineralys Therapeutics, Inc. (MLYS)
In a report released yesterday, Tim Anderson from Bank of America Securities maintained a Buy rating on Mineralys Therapeutics, Inc. (MLYS – ...
BioWorld4d
Mineralys sees a double drop in blood pressure and a stock pop
Positive top-line data from phase II and III studies of lorundrostat for treating uncontrolled or resistant hypertension ...
Stocks to Watch: Cognizant Technology Solutions, Mineralys Therapeutics, PDF Solutions
Mineralys Therapeutics said it plans to release data from two recent trials involving lorundrostat, a drug the biopharmaceutical company is developing as a treatment for high blood pressure. Shares ...
Mineralys Therapeutics announces results from Launch-HTN, Advance-HTN trials
Mineralys Therapeutics (MLYS) announced positive topline data from its Launch-HTN Phase 3 and Advance-HTN Phase 2 trials evaluating the ...